ABSTRACT
BACKGROUND: Core needle biopsy (CNB) method is a common method and a gold standard for the diagnosis of breast lesions. The purpose of this study was to compare the results of visual inspection of ultrasound guided biopsy specimens with pathologic outcomes in patients with breast lesions. METHODS: This cross-sectional descriptive was conducted on 600 patients with breast lesions who were candidates for ultrasonography with CNB were entered into the study. Then, patients underwent sonography with needle biopsy, in a sample taken by The radiologist classifies the breast mass according to its consistency and shape based on observation to the malignant or benign, as well as the Breast Imaging Reporting and Data System or Mass BIRADs. visual inspection results were compared with the CNB pathology of patients. RESULTS: In this study, the sensitivity and specificity of the lesion were 97.48% and 94.10%, respectively, and positive and negative predictive values of this test were 85.64% and 99.05%, respectively. CONCLUSION: Given that the sensitivity and specificity of the biopsy lesions to detect the type of mass was higher than the pathology of the sample, it can be ensured that the biopsy of breast lesions, especially in sizes less than 10 mm in time Increased the biopsy and reduced the number of cores taken from the lesion.
ABSTRACT
BACKGROUND: Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients. METHODS: In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLL patients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated. RESULTS: In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073). CONCLUSION: Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLL patients.
ABSTRACT
INTRODUCTION: Prostate cancer is one of the most common cancers in men which is mostly slow growing and responses well to treatments if early diagnosed. Urinary prostate cancer antigen 3 (PCA3) assay is a new method with effective results in diagnosing prostate cancer. The aim of this present study was evaluate the correlation between urinary PCA3 and Gleason scores in patients who are suspicious of prostate cancer and undergo tissue biopsies. METHODS: This is a cross-sectional study which was performed in 2017-2018. The patients included this study complain of prostate problems and were selected from Nour hospital, Ali-Asghar hospital and Ordibehesht clinic in Tehran, Iran. Urinary PCA3 levels were checked in all patients and then they went under prostate biopsies. Amounts of PCA3 and Gleason scores were collected and analyzed using SPSS software. FINDINGS: We evaluated a total number of 80 patients. 40 patients had prostate cancer and 40 had no cancer. We indicated that no significant relation was reported between Gleason scores and urinary PCA3 levels. Levels of urinary PCA3 were higher in patients with prostate cancer than in patients with no cancer (P=0.007). DISCUSSION: Generally, urinary PCA3 test is indicated as a non-invasive method to improve the specificity of prostate cancer diagnosis and its potential predictive value was studied in numerous clinical researches, but here we found higher PCA3 levels in patients with prostate cancer than in patients with and other prostate problems. We conclude that PCA3 functions as a diagnostic test and its changes in prostate cancer need to be further studied in different populations and races.
